Migraine

Jun 09, 2021

Migraine is a medical condition characterized by recurrent headaches that can last from 4 to 72 hours and often results in a wide range of symptoms. It is mainly associated with a painful headache, however, the affected person may experience nausea, vomiting, disturbed vision, sensitivity to light, sound, and smell...

Feb 25, 2020

Formerly known as eptinezumab, Lundbeck’s Vyepti has received the recommendation from the US FDA for preventing migraine in adults. Estimated to affect women twice as compared to men, around 1.3billion people worldwide, and approximately 38 million people in the US are afflicted with Migraine.  With the gree...

Oct 07, 2019

The World Health Organization’s disability rating for migraine ranks it as the 19th most common reason for disability. According to the Migraine Trust Organization, Migraine is ranked as the 7th most disabling disease in the world (a cause for a loss of 2.9% of all years of life lost to disability/YLDs). The ...

Jun 07, 2019

In layman’s language, Cluster headache is a headache disorder that occurs in cyclical patterns. The term cluster headache itself defines the condition that these attacks occur in groups, or “clusters.” During a cluster cycle, brief, excruciatingly severe headache attacks recur between 1-8 times per day. Known as on...

Jul 17, 2018

Alkermes Gets FDA approval for Aristada Initio (aripiprazole lauroxil) as Part of  Schizophrenia Treatment Combination  Alkermes has announced that the U.S. FDA approved ARISTADA INITIO (aripiprazole lauroxil) for the initiation of ARISTADA (aripiprazole lauroxil), a long-acting injectable atypical antipsychotic f...

Nov 28, 2017

Biohaven Completes Enrollment of Rimegepant in Second Pivotal Phase 3 Clinical Trial for the treatment of Migraine Biohaven Pharmaceutical has recently announced the completion of enrollment of their study BHV3000-302 in Phase 3. The company is examining the safety and efficacy of Rimegepant for the treatment of Mi...